Anne-Marie Duliege Sells 153,000 Shares of Rigel Pharmaceuticals, Inc. (RIGL) Stock

Share on StockTwits

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EVP Anne-Marie Duliege sold 153,000 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $3.50, for a total value of $535,500.00. Following the transaction, the executive vice president now directly owns 115,500 shares in the company, valued at approximately $404,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Anne-Marie Duliege also recently made the following trade(s):

  • On Tuesday, September 4th, Anne-Marie Duliege sold 16,500 shares of Rigel Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $57,915.00.
  • On Monday, July 2nd, Anne-Marie Duliege sold 5,000 shares of Rigel Pharmaceuticals stock. The shares were sold at an average price of $2.79, for a total value of $13,950.00.

RIGL remained flat at $$3.10 during trading on Friday. The company had a trading volume of 1,040,523 shares, compared to its average volume of 2,506,607. The firm has a market capitalization of $534.28 million, a PE ratio of -5.00 and a beta of 1.07. Rigel Pharmaceuticals, Inc. has a 52-week low of $2.56 and a 52-week high of $4.71.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $1.79 million for the quarter, compared to analyst estimates of $0.30 million. Equities analysts anticipate that Rigel Pharmaceuticals, Inc. will post -0.65 earnings per share for the current year.

RIGL has been the topic of several recent analyst reports. BidaskClub downgraded Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, June 21st. Zacks Investment Research upgraded Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Wednesday, July 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price target on shares of Rigel Pharmaceuticals in a research report on Wednesday, August 8th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Rigel Pharmaceuticals in a research report on Thursday, August 9th. Finally, Citigroup assumed coverage on Rigel Pharmaceuticals in a report on Monday, August 27th. They issued a “buy” rating and a $8.50 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Rigel Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $7.59.

Large investors have recently made changes to their positions in the business. Bank of Montreal Can acquired a new stake in shares of Rigel Pharmaceuticals in the second quarter worth about $139,000. Canada Pension Plan Investment Board bought a new position in shares of Rigel Pharmaceuticals in the second quarter worth about $142,000. Cubist Systematic Strategies LLC increased its stake in shares of Rigel Pharmaceuticals by 199.9% in the second quarter. Cubist Systematic Strategies LLC now owns 60,559 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 40,366 shares during the period. Lido Advisors LLC bought a new position in shares of Rigel Pharmaceuticals in the first quarter worth about $195,000. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of Rigel Pharmaceuticals in the first quarter worth about $232,000. 94.23% of the stock is owned by institutional investors.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy.

Featured Article: Penny Stocks

Insider Buying and Selling by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply